Literature DB >> 3323313

Dopamine blockade abolishes the exaggerated natriuresis of essential hypertension.

P Coruzzi1, L Musiari, A Biggi, C Ravanetti, A Novarini.   

Abstract

We studied natriuresis during central hypervolaemia by immersing eight normal subjects and eight patients with uncomplicated essential hypertension up to the neck in water, either in the absence (study 1) or presence (study 2) of dopamine blockade by metoclopramide. Water immersion without metoclopramide induced an exaggerated natriuresis in hypertensives compared with normotensives (P less than 0.001). This occurred in the presence of identical hormonal (plasma renin activity, plasma aldosterone and prolactin), renal (creatinine clearance) and pressor responses in both groups (study 1). The marked natriuresis seen during water immersion alone in normotensives was significantly blunted (P less than 0.02) but not abolished during water immersion with addition of metoclopramide. On the other hand, the exaggerated natriuresis found in hypertensives during water immersion alone was completely abolished during water immersion plus dopamine blockade by metoclopramide (study 2). Similar hormonal, renal and pressor changes were detected in both normotensive and hypertensive subjects during water immersion plus metoclopramide administration. Our data demonstrate that metoclopramide abolishes the exaggerated natriuretic response seen in hypertensives during volume expansion produced by water immersion, and suggest that dopamine may play a critical role in mediating the hypernatriuresis of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323313     DOI: 10.1097/00004872-198710000-00013

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  1 in total

1.  Increased urinary 6-keto-PGF1 alpha excretion during water immersion is blunted by metoclopramide in normal man.

Authors:  P Minuz; P Coruzzi; F Paluani; C Ravanetti; C Lechi; P Delva; A Lechi; A Novarini
Journal:  J Endocrinol Invest       Date:  1989-10       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.